An observational study in Opioid Use Disorder, Bereavement and Overdose of Opiate, sponsored by Cambridge Health Alliance. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-04.
Sponsored by Cambridge Health Alliance · Observational
This study aims to analyze the needs of those who have lost a loved one to opioid-related death and/or those currently supporting a loved one in treatment for Opioid Use Disorder. Mental health status related to the death or support of a loved one will be assessed through a survey and through the use of several modules of the CAT-MH (computerized adaptive testing-mental health suite) questionnaire.
This study aims to establish the level of needs in the community among those who have lost loved ones to opioid overdose and/or currently support those in opioid addiction recovery. This study aims to analyze the needs of those who have lost a loved one to opioid-related death and/or those currently supporting a loved one in treatment for Opioid Use Disorder. The study will evaluate the mental health status for each study participant through a primary survey as well as current participant mental health status through the use of several modules of the CAT-MH adaptive testing questionnaire. CAT-MH will be used to rapidly measure severity levels of depression, anxiety, and substance use risk after participants complete the primary survey. The primary survey assesses the immediate impact of overdose death by a loved one and recognition of the onset of opioid addiction in the years after the event on family and community members. The primary survey will compare the impact of loss and/or recovery support on mental health and substance use at specified time points before and after the loss and/or an individual finding out about a loved one's opioid addiction. The primary survey will also evaluate attitudes in this population about mindfulness and self-compassion skills training, openness to technology and various treatment options, current and past levels of depression, anxiety and grief, as well as thematic areas of need specific to those who have lost a loved one to opioid overdose and/or currently support a loved one in opioid addiction recovery.
1,472 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
This study's enrollment of 578 is above the median of 129 across 184 observational studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →Cambridge Health Alliance is the lead sponsor of 52 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The population will be selected by an email send both to collaborating organizations that provide peer support for those with addiction-related overdose and to healthcare systems that provide care for people with OUD to share with people in their communities who may have lost a loved one to opioid-related death.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
These individuals will complete the study survey for their designated experience both supporting a loved one in treatment for Opioid Use Disorder, and having lost a loved one to opioid-related death.
Other: Survey
These individuals will complete the study survey for their designated experience supporting a loved one in treatment for Opioid Use Disorder.
Other: Survey
These individuals will complete the study survey for their designated experience losing a loved one to opioid-related death.
Other: Survey
All study participants will be asked to complete two surveys relevant to their personal experience either losing a loved one to opioid-related death, supporting a loved on in recovery for Opioid Use Disorder, or both.
Establish the percentage of adults who have lost a loved one to opioid overdose who had increased substance use in the year after their loss.
This self-report aim will be assessed via participant survey response asking for recollection of substance use before and after the loss.
Time frame: Day 1
Establish the percentage of adults who have lost a loved one to opioid overdose who received mental health treatment in the year after their loss.
This self-report aim will be assessed via participant survey response asking for recollection of mental health treatment before and after the loss.
Time frame: Day 1
Compare the level of negative impact on substance use and mental health status in the year after loss due to overdose with the impact on substance use and mental health in the year after becoming aware of a child's opioid addiction.
This aim will be assessed via participant survey response between cohorts
Time frame: Day 1
Prolonged Grief
Aa version of the prolonged grief (PG-13) scale will be used to assess presence of prolonged grief after date of loss event.
Time frame: Day 1
Depression
This aim will be assessed via CAT-MH's CAT-DI adaptive test (computerized adaptive testing-mental health suite for depression).
Time frame: Day 1
Establish the percentage of adults who have lost a loved one to opioid overdose who had worsening eating disorders, OCD (Obsessive-compulsive disorder), or problematic sexual behaviors in the year after their loss.
This aim will be assessed via participant survey self-report responses.
Time frame: Day 1
Anxiety
This aim will be assessed via CAT-MH's CAT-Anxiety adaptive test
Time frame: Day 1
PTSD symptoms
This aim will be assessed via CAT-MH's CAT-PTSD adaptive test
Time frame: Day 1
Establish the percentage of adults who have lost a loved one to opioid overdose who had worsening depression in the year after their loss.
This self-report aim will be assessed via participant survey response asking for recollection of depression symptoms before and after the loss.
Time frame: Day 1
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Apr 2024, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cambridge Health Alliance